Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02333045 · ClinicalTrials.gov registry record · NA
Characterization and Modulation of Mucosal Immunity for HIV Prevention in Women
A NA study, sponsored by Emory University.
- Terminated
- Registry status
- NA
- Development phase
- 4
- Enrollment target
NCT02333045: Clinical Trial NA study, sponsored by Emory University.
NCT02333045 is a NA study that was terminated before completion, run by Emory University. The registered enrollment target is 4 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (100% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02333045, a NA study, was terminated before completion, sponsored by Emory University.
- TERMINATED
- Registry status
- NA
- Development phase
- 4 participants
- Enrollment target
Study Summary
This study seeks to understand the immune cells in the cervical fluid of in the blood and genital tract of HIV-negative healthy female volunteers and to see if these cells can be modified using a combined anti-viral and antiinflammatory drug called maraviroc, a medicine used in the treatment of HIV infection.
Primary Outcome
The count of CCR5+CD4+ T cells in the genital tract, before participants began study treatment, after 7 days of treatment, and during the post-treatment drug elimination period. The precise role of CCR5+CD4+ T cells in the female genital tract is unknown, however, higher cell counts may suggest the potential for more HIV target cells in the genital tract.
Interventions
- DRUG Truvada qd
- DRUG Maraviroc 300 qd
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4 participants |
| Start Date | 2015-01 |
| Est. Completion | 2016-10-28 |
| Phase | NA |
Why NCT02333045 stopped before completion
NCT02333045 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 4 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (100% lower).
The record links to 0 conditions, and to 2 interventions - of which Truvada qd is the first listed.
NCT02333045 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02333045 about?
NCT02333045 is a clinical study titled "Characterization and Modulation of Mucosal Immunity for HIV Prevention in Women". This study seeks to understand the immune cells in the cervical fluid of in the blood and genital tract of HIV-negative healthy female volunteers and to see if these cells can be modified using a combined anti-viral and antiinflammatory drug called maraviroc, a medicine used in the treatment of HIV ...
What is the current status of trial NCT02333045?
This trial is currently terminated. It is a NA study. The enrollment target is 4 participants. The study started on 2015-01. Estimated completion is 2016-10-28.
What interventions are being tested in trial NCT02333045?
The interventions under investigation include: Truvada qd (DRUG), Maraviroc 300 qd (DRUG).
Who is sponsoring clinical trial NCT02333045?
This trial is sponsored by Emory University, which has 1,208 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02333045's enrollment target sits among peer trials
4 1996th of 2000 higher than 5 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia